Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043
Source: The Oncologist - Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva